share_log

6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Ema Priority Medicines (Prime) Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer

6-K: Gsk's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives Ema Priority Medicines (Prime) Designation in Relapsed Extensive-Stage Small-Cell Lung Cancer

6-K:Gsk的B7-H3靶向抗体药物偶联物Gsk'227获得Ema优先药物(Prime)称号,用于治疗复发性广泛期小细胞肺癌
美股SEC公告 ·  12/16 22:08
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息